Bevacizumab plus FU/LV:new first-line chemotherapy of metastatic colorectal cancer[J]. Journal of Evidence-Based Medicine, 2003, 3(4): 221-223. DOI: 10.3969/j.issn.1671-5144.2003.04.008
|
Citation:
|
Bevacizumab plus FU/LV:new first-line chemotherapy of metastatic colorectal cancer[J]. Journal of Evidence-Based Medicine, 2003, 3(4): 221-223. DOI: 10.3969/j.issn.1671-5144.2003.04.008
|
Bevacizumab plus FU/LV:new first-line chemotherapy of metastatic colorectal cancer[J]. Journal of Evidence-Based Medicine, 2003, 3(4): 221-223. DOI: 10.3969/j.issn.1671-5144.2003.04.008
|
Citation:
|
Bevacizumab plus FU/LV:new first-line chemotherapy of metastatic colorectal cancer[J]. Journal of Evidence-Based Medicine, 2003, 3(4): 221-223. DOI: 10.3969/j.issn.1671-5144.2003.04.008
|
DownLoad: